贝沙罗汀在皮肤T细胞淋巴瘤治疗中的实际应用：低剂量时的疗效与耐受性 - Suppr

Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses.

作者信息

Rouanet Jacques, Joulie Ines, Lambert Celine, D'Incan Michel

机构信息

Dermatology and Oncodermatology Department, CHU Clermont-Ferrand, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.

出版信息

Acta Derm Venereol. 2022 Jul 7;102:adv00746. doi: 10.2340/actadv.v102.718.

DOI:10.2340/actadv.v102.718

PMID:35312021

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9631282/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2869/9631282/1ddade3c51bb/ActaDV-102-718-g001.jpg

相似文献

Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses.

Acta Derm Venereol. 2022 Jul 7;102:adv00746. doi: 10.2340/actadv.v102.718.

Topical and oral bexarotene.

Dermatol Ther. 2013 Sep-Oct;26(5):400-3. doi: 10.1111/dth.12087.

About the cutaneous targets of bexarotene in CTCL patients.

Exp Dermatol. 2010 Aug;19(8):e299-301. doi: 10.1111/j.1600-0625.2009.00995.x.

Extracutaneous tumour mass following bexarotene and interferon therapy of primary cutaneous CD30+ large cell lymphoma.

Acta Derm Venereol. 2006;86(3):274-5. doi: 10.2340/00015555-0059.

Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.

J Dermatolog Treat. 2009;20(3):169-76. doi: 10.1080/09546630802562427.

Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma.

J Dermatol. 2020 May;47(5):443-451. doi: 10.1111/1346-8138.15310. Epub 2020 Mar 18.

Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.

J Dtsch Dermatol Ges. 2003 Oct;1(10):785-9. doi: 10.1046/j.1439-0353.2003.03711.x.

Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.

Acta Derm Venereol. 2012 May;92(3):258-63. doi: 10.2340/00015555-1359.

[Cutaneous cytotoxic T-cell lymphoma].

Hautarzt. 2011 May;62(5):329-32. doi: 10.1007/s00105-011-2165-2.

Optimizing bexarotene therapy for cutaneous T-cell lymphoma.

J Am Acad Dermatol. 2004 Sep;51(3):482; author reply 482-3. doi: 10.1016/j.jaad.2003.04.006.

引用本文的文献

Role of Retinoids and Their Analogs in the Treatment of Cutaneous T-cell Lymphoma: A Systematic Review.

Cureus. 2024 Sep 13;16(9):e69318. doi: 10.7759/cureus.69318. eCollection 2024 Sep.

Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma.

Drugs R D. 2024 Jun;24(2):227-238. doi: 10.1007/s40268-024-00465-7. Epub 2024 Jun 13.

本文引用的文献

Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy.

J Dermatol. 2020 Jun;47(6):636-640. doi: 10.1111/1346-8138.15322. Epub 2020 Mar 24.

The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.

Blood. 2019 Apr 18;133(16):1703-1714. doi: 10.1182/blood-2018-11-881268. Epub 2019 Jan 11.

Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.

Am J Ther. 2016 May-Jun;23(3):e749-56. doi: 10.1097/MJT.0000000000000056.

Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature.

Expert Opin Pharmacother. 2013 Sep;14(13):1711-21. doi: 10.1517/14656566.2013.810718. Epub 2013 Jul 10.

Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.

Acta Derm Venereol. 2012 May;92(3):258-63. doi: 10.2340/00015555-1359.

Bexarotene therapy for mycosis fungoides and Sézary syndrome.

Br J Dermatol. 2009 Jun;160(6):1299-307. doi: 10.1111/j.1365-2133.2009.09037.x. Epub 2009 Feb 16.

[Mycosis fungoid treated with oral bexarotene: study of 13 cases].

Med Clin (Barc). 2007 Nov 10;129(17):677. doi: 10.1157/13112095.

The optimal use of bexarotene in cutaneous T-cell lymphoma.

Br J Dermatol. 2007 Sep;157(3):433-40. doi: 10.1111/j.1365-2133.2007.07975.x. Epub 2007 Jun 6.

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.

J Clin Oncol. 2001 May 1;19(9):2456-71. doi: 10.1200/JCO.2001.19.9.2456.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses.

作者信息

Rouanet Jacques, Joulie Ines, Lambert Celine, D'Incan Michel

机构信息

Dermatology and Oncodermatology Department, CHU Clermont-Ferrand, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.

出版信息

Acta Derm Venereol. 2022 Jul 7;102:adv00746. doi: 10.2340/actadv.v102.718.

DOI:10.2340/actadv.v102.718

PMID:35312021

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9631282/

Abstract

摘要

相似文献

Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses.

Acta Derm Venereol. 2022 Jul 7;102:adv00746. doi: 10.2340/actadv.v102.718.

Topical and oral bexarotene.

Dermatol Ther. 2013 Sep-Oct;26(5):400-3. doi: 10.1111/dth.12087.

About the cutaneous targets of bexarotene in CTCL patients.

Exp Dermatol. 2010 Aug;19(8):e299-301. doi: 10.1111/j.1600-0625.2009.00995.x.

Extracutaneous tumour mass following bexarotene and interferon therapy of primary cutaneous CD30+ large cell lymphoma.

Acta Derm Venereol. 2006;86(3):274-5. doi: 10.2340/00015555-0059.

Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.

J Dermatolog Treat. 2009;20(3):169-76. doi: 10.1080/09546630802562427.

Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma.

J Dermatol. 2020 May;47(5):443-451. doi: 10.1111/1346-8138.15310. Epub 2020 Mar 18.

Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.

J Dtsch Dermatol Ges. 2003 Oct;1(10):785-9. doi: 10.1046/j.1439-0353.2003.03711.x.

Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.

Acta Derm Venereol. 2012 May;92(3):258-63. doi: 10.2340/00015555-1359.

[Cutaneous cytotoxic T-cell lymphoma].

Hautarzt. 2011 May;62(5):329-32. doi: 10.1007/s00105-011-2165-2.

Optimizing bexarotene therapy for cutaneous T-cell lymphoma.

J Am Acad Dermatol. 2004 Sep;51(3):482; author reply 482-3. doi: 10.1016/j.jaad.2003.04.006.

引用本文的文献

Role of Retinoids and Their Analogs in the Treatment of Cutaneous T-cell Lymphoma: A Systematic Review.

Cureus. 2024 Sep 13;16(9):e69318. doi: 10.7759/cureus.69318. eCollection 2024 Sep.

Drugs R D. 2024 Jun;24(2):227-238. doi: 10.1007/s40268-024-00465-7. Epub 2024 Jun 13.

本文引用的文献

Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy.

J Dermatol. 2020 Jun;47(6):636-640. doi: 10.1111/1346-8138.15322. Epub 2020 Mar 24.

The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.

Blood. 2019 Apr 18;133(16):1703-1714. doi: 10.1182/blood-2018-11-881268. Epub 2019 Jan 11.

Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.

Am J Ther. 2016 May-Jun;23(3):e749-56. doi: 10.1097/MJT.0000000000000056.

Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature.

Expert Opin Pharmacother. 2013 Sep;14(13):1711-21. doi: 10.1517/14656566.2013.810718. Epub 2013 Jul 10.

Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.

Acta Derm Venereol. 2012 May;92(3):258-63. doi: 10.2340/00015555-1359.

Bexarotene therapy for mycosis fungoides and Sézary syndrome.

Br J Dermatol. 2009 Jun;160(6):1299-307. doi: 10.1111/j.1365-2133.2009.09037.x. Epub 2009 Feb 16.

[Mycosis fungoid treated with oral bexarotene: study of 13 cases].

Med Clin (Barc). 2007 Nov 10;129(17):677. doi: 10.1157/13112095.

The optimal use of bexarotene in cutaneous T-cell lymphoma.

Br J Dermatol. 2007 Sep;157(3):433-40. doi: 10.1111/j.1365-2133.2007.07975.x. Epub 2007 Jun 6.

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.

J Clin Oncol. 2001 May 1;19(9):2456-71. doi: 10.1200/JCO.2001.19.9.2456.

Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献